Common oral hypoglycemic agents in the treatment of kidney disease

  Sulfonylurea generation 1: including methanesulfonylurea, chlorosulfonylurea, acetylbenzenesulfonylcyclohexyl urea, excreted through the kidneys and should not be used in CRF to avoid severe hypoglycemia.  Sulfonylurea generation 2: Glipizide, glibenclamide/gliclazide are excreted by kidney, same as generation 1. Glibenclamide, metabolized by liver, but the metabolite will produce hypoglycemia, use with caution for Ccr<50ml/min. Glucophage (gliquidone) available 30-80 mg/day.  Sulfonylurea 3 generation: Glimepiride (Amoxicillin) 0.5-1mg/d Rapid insulin secretagogue (mealtime glucose regulator): Repaglinide (Novaluron) 30-60 min peak, half-life <1 hour, 0.5-1mg tid Biguanides: pay attention to lactic acidosis, ccr<80ml/min prohibited.  Bystrophin: not for use in indigestion, pregnancy and lactation.  Insulin sensitizer: Thiazolidine II. Rosiglitazone (Vindia) 4mg qd-bid, 12 weeks as regulation cycle.